

Annex G

– Amendment A (in red) and Amendment D (in green)

1. A p a ma euti a ompositio omp isi g a iposome wit i w i NA e odi g a immu oge of i te est ise apsu ated, w e ei t e iposome omp ises at east o e ipid w i i udes a po yet ye e gy o moiety, su t at po yet ye e gy o is p ese t on the liposo e's exterior, wherein the average olecular ass of the po yet ye e gy o is betwee 1kDa a d 3kDa, w e ei t e p a ma euti a ompositio i udes a T is buffe , w e ei t e iposome omp ises a ipid wit a atio i ead g oup a d a ipid wit a zwitte io i ead g oup, a d w e ei t e iposome is fo med f om a mixtu e of ipids, w e ei t e p opo tio of t ose ipids w i a e PEGy ated is ess t a 10 mo % of t e tota amou t of ipids, a d w e ei t e emai de is made of 35-50 mo % o este o , 30-70 mo % atio i ipid a d 5-15 mo % DSPC, a d w e ei t e ipid wit a atio i ead g oup is ot D i DMA (1,2-di i o ey oxy-N,N-dimet y -3-ami op opa e).

~~3. T e p a ma euti a ompositio of a yp e edi g aim, w e ei t e iposome omp ises a ipid wit a atio i ead g oup.~~

~~. T e p a ma euti a ompositio of a yp e edi g aim, w e ei t e iposome omp ises a ipid wit a zwitte io i ead g oup.~~

*C aims not shown above remain as granted (subject to renumbering of c aims and of cross-referenced c aims).*

## Annex H

### 1 – Amendment B (in red) and Amendment D (in green)

. A harma eu i al m si i n m rising a li s me wi hin whi h RNA en ding an immun gen fin eres is en a sula ed, wherein he li s me m rises a leas ne li id whi h in ludes a lye hylene gly l m ie y, su h ha lye hylene gly l is resen on th liposom 's xt rior, wh r in th av rag mol cular mass of th lye hylene gly l is be ween kDa and 3kDa, wherein he harma eu i al m si i n in ludes a Tris buffer, wherein he li s me m rises a li id wi h a a i ni head gr u and a li id wi h a zwi eri ni head gr u , and wherein he li s me is f rmed fr m a mix ure f li ids, wherein 2 m l% f he al li id is a PEG-DMG, and wherein he remainder is made f 35-50 m l% h les er l, 30- o m l% a i ni li id and 5- 5 m l% DSP , and wherein he li id wi h a a i ni head gr u is n DlinDMA ( ,2-dilin leyl xy-N,N-dime hyl-3-amin r ane).

~~3. The harma eu i al m si i n f any re eding laim, wherein he li s me m rises a li id wi h a a i ni head gr u .~~

~~4. The harma eu i al m si i n f any re eding laim, wherein he li s me m rises a li id wi h a zwi eri ni head gr u .~~

*Claims not shown above remain as granted (subject to renumbering of claims and of cross-referenced claims).*

## Annex I

### – Amendment C

The text of granted claim 1 is shown in black for clarity, with the proposed amendment shown in green.

1 A pharmaceutical composition comprising a liposome within which RNA encoding an immunogen of interest is encapsulated, wherein the liposome comprises at least one lipid which includes a polyethylene glycol moiety, such that polyethylene glycol is present on the liposome's exterior, wherein the average molecular mass of the polyethylene glycol is between 1kDa and 10kDa, wherein the pharmaceutical composition includes a Tris buffer, and wherein the liposome does not comprise EG-DMG (EG-(1,2-Dimyristoyl-sn-lycero-3-phosphoethanolamine))

The remaining claims are as granted.